AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03050450
Drug: 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
Trial: NCT00907322
Drug: Dimebon
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet; 20 mg Dimebon, single dose
Trial: NCT00907322
Drug: Dimebon
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet; 40 mg Dimebon, single dose
Trial: NCT00973024
Drug: JNJ-42160443 10 mg
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
Trial: NCT00907322
Drug: Dimebon
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet; 60 mg Dimebon, single dose
Trial: NCT00907322
Drug: Dimebon
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet; placebo, single dose
Trial: NCT01208324
Drug: estrogen patch
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
Trial: NCT01208324
Drug: Amino acids
RxNorm normalized name: Amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
Trial: NCT04004338
Drug: Kyprolis
RxNorm normalized name: Kyprolis
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receiving kyprolis (carfilzomib)
Trial: NCT00570778
Drug: indacaterol/glycopyrrolate
RxNorm normalized name: indacaterol/glycopyrrolate 27.5 mcg-15.6 mcg INHALATION CAPSULE, WITH INHALATION DEVICE
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
Trial: NCT00570778
Drug: indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
Trial: NCT01491178
Drug: Prazaxa
RxNorm normalized name: Pradaxa
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate
Trial: NCT02014506
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/M2 once daily IV on days -7 to -2
Trial: NCT02456207
Drug: SCT400
RxNorm normalized name: Immunoglobulin igg1, anti-(human cd20 antigen) (human-mus musculus monoclonal disulfide sct400 .gamma.1-chain), disulfide with human-mus musculus monoclonal sct400 .kappa.-chain, dimer
DrugBank: Ripertamab (DB16314)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02456207
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00301145
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02644252
Drug: Day 1: Cisplatin 75 mg/m2
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02644252
Drug: Day 1: Vinorelbine 25 mg/m2
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02644252
Drug: Day 8: Capsule vinorelbine 50 mg/m2
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02644252
Drug: Day 1: Carboplatin AUC=5
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02644252
Drug: Day 1: Vinorelbine 30 mg/m2
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02644252
Drug: Day 8: Capsule vinorelbine 60 mg/m2
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03171584
Drug: Terbinafine
RxNorm normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral antifungal drugs
Trial: NCT00819000
Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS therapies (listed above) used according to prescribers' instructions.
Trial: NCT03637361
Drug: REL-1017
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
Trial: NCT00438360
Drug: Cyclosporine A microemulsion
RxNorm normalized name: cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
Trial: NCT01309997
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02583633
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02583633
Drug: nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02029456
Drug: 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
RxNorm normalized name: activated charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02691910
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
Trial: NCT02691910
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
Trial: NCT01231334
Drug: Dapsone plus Adapalene
RxNorm normalized name: Dapsone
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
Trial: NCT02173639
Drug: BI 1356/metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fixed dose combination tablet
Trial: NCT02173639
Drug: BI 1356
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00641407
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 IU bedtime and then titration
Trial: NCT02173639
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00304616
Drug: Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00588237
Drug: Paclitaxel,Cisplatin, Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
Trial: NCT00418132
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
Trial: NCT00418132
Drug: Placebo thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
Trial: NCT03272477
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
Trial: NCT02912234
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multiple-dose clarithromycin and single-dose Apixaban
Trial: NCT01296256
Drug: Bendamustine-EAM
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
Trial: NCT03272477
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
Trial: NCT02096952
Drug: Methylphenidate extended-release liquid formulation
RxNorm normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02350335
Drug: Nicotine (transdermal)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
Trial: NCT00372619
Drug: clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV for 5 days
Trial: NCT00372619
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00437957
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 Mg/m2/day for all Cohorts
Trial: NCT00437957
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
Trial: NCT02684617
Drug: dinaciclib
RxNorm normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
Trial: NCT00203736
Drug: Sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00203736
Drug: Artesunate plus sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00833963
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive trastuzumab as determined by their treating physicians' standards of care.
Trial: NCT00833963
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive pertuzumab as determined by their treating physicians' standards of care.
Trial: NCT00833963
Drug: Ado-Trastuzumab Emtansine
RxNorm normalized name: Ado-Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
Trial: NCT01118403
Drug: Sultamicillin
RxNorm normalized name: sultamicillin
DrugBank: Sultamicillin (DB12127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
Trial: NCT04301934
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current standard treatment for recurrent UTIs in postmenopausal women
Trial: NCT00969306
Drug: Chloroquine, A-CQ 100
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form.
Trial: NCT03248531
Drug: Bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Bimekizumab in different dosages (dose 1 and 2).
Trial: NCT03248531
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab in different dosages (dose 1, 2 and 3).
Trial: NCT00815568
Drug: fludarabine phosphate, busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
Trial: NCT01345929
Drug: CXA-201
RxNorm normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXA-201 IV infusion (1500mg q8) for 7 days
Trial: NCT01345929
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin IV infusion (750mg qd) for 7 days
Trial: NCT03396497
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
Trial: NCT03438708
Drug: Axitinib Oral Tablet [Inlyta]
RxNorm normalized name: axitinib Oral Tablet [Inlyta]
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
Trial: NCT01901614
Drug: Retrobulbar Block or General Anesthesia
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00355862
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus based immunosuppression
Trial: NCT01650649
Drug: Lofexidine HCl
RxNorm normalized name: lofexidine HCl
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
Trial: NCT01650649
Drug: Lofexidine-matching sugar pill
RxNorm normalized name: lofexidine Pill
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
Trial: NCT02742233
Drug: saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment
Trial: NCT02517996
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
Trial: NCT06238336
Drug: CAR-T cell therapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
Trial: NCT01841021
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
Trial: NCT03272477
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
Trial: NCT02526953
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
Trial: NCT02526953
Drug: Mitomycins
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m2, IV, on day 1. Number of infusions: 1.
Trial: NCT02526953
Drug: Mitomycins
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mg/m2, IV, on day 1. Number of infusions: 1.
Trial: NCT00149799
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
Trial: NCT03964168
Drug: Biologic Agent
RxNorm normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who discontinued a bioloic agent
Trial: NCT01744067
Drug: Omega-3 fatty acids
RxNorm normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
Trial: NCT03034005
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1600 ug inhaled daily for 6 weeks
Trial: NCT00932438
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/sqm, IV infusion every two weeks
Trial: NCT00932438
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week